Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
688177.SS
STRONG SELLREMOVEBio-Thera Solutions, Ltd. · Healthcare · China · $1.2B · Avg Vol: $8M/d
Bio-Thera Solutions is a pre-profit biotech firm with high R&D cash burn, failing our Terry Smith quality compounder criteria and lacking internal manufacturing scale.
COMPANY DESCRIPTION
Bio-Thera Solutions, Ltd. develops innovative biologics and biosimilars targeting oncology, autoimmune, and cardiovascular diseases. The company's competitive moat is established by its robust pipeline of biosimilars approved in both China and highly regulated international markets like the US and Europe. It is a leading Chinese biotechnology firm with advanced antibody discovery platforms and a proven global regulatory track record.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 67M | 104M | 110M | 138M | 27.1% |
| EPS | -0.17 | -0.14 | -0.18 | -0.12 | — |
| Shares | 414M | 414M | 414M | 414M | 0.0% |
| Debt | 1M | 71M | 93M | 101M | 316.3% |
| Equity | 238M | 179M | 105M | 56M | -38.4% |
| Op CF | -61M | -68M | -8M | -12M | — |
| Inv CF | -36M | 6M | 18M | -1M | — |
| Fin CF | -4M | 58M | 13M | 6M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 688177.SS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 688177.SS | Bio-Thera Solutions, Ltd.(you) | $1.2B | 5 | STRONG SELL |
| 6938.HK | Suzhou Ribo Life Science Co | $1.3B | 5 | STRONG SELL |
| 6872.HK | TENNOR THERAP-B | $1.4B | 2 | STRONG SELL |
| 2659.HK | Shanghai Bao Pharmaceuticals Co., Ltd. | $1.0B | 10 | STRONG SELL |
| 688068.SS | Beijing Hotgen Biotech Co., Ltd. | $1.2B | 12 | STRONG SELL |
| 2617.HK | TransThera Sciences (Nanjing), Inc. | $1.8B | 4 | STRONG SELL |
| 300294.SZ | China Resources Boya Bio-pharmaceutical Group Co.,Ltd | $1.2B | 14 | STRONG SELL |
| 6855.HK | Ascentage Pharma Group International | $1.9B | 4 | STRONG SELL |
| 688443.SS | Chongqing Genrix Biopharmaceutical Co., Ltd. | $1.5B | 12 | STRONG SELL |
| 688062.SS | Mabwell (Shanghai) Bioscience Co., Ltd. | $2.0B | 3 | STRONG SELL |
Peer medians: ROE 4.8% · P/E 27.8x · Gross margin 53.0%